The reproductive and metabolic effect of rosiglitazone on Chinese women with
polycystic ovarian syndrome--a double-blind randomized placebo-controlled study.
Author(s): Lam PM, Tam WH, Ma RC, Cheung LP, Tsui MH, Tong PC, Chow FC, Lam CW, Chan MH,
Chan JC, Haines CJ.
Affiliation(s): Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong,
People's Republic of China.
Publication date & source: 2011, Fertil Steril. , 96(2):445-451
OBJECTIVE: To investigate whether an insulin sensitizer has any effect on
amenorrhea and clinical and biochemical hyperandrogenism in Chinese women with
polycystic ovarian syndrome (PCOS).
DESIGN: Randomized controlled double-blind trial.
SETTING: A tertiary referral center, Hong Kong.
PATIENT(S): Chinese women who fulfilled the Rotterdam criteria of PCOS (n = 70).
INTERVENTION(S): Rosiglitazone 4 mg daily for the first month followed by 4 mg
twice daily for 11 months.
MAIN OUTCOME MEASURE(S): Menstrual status as well as clinical and biochemical
hyperandrogenism.
RESULT(S): There is a significantly higher rate of regular menses among the
treatment arm (16 [50.0%] of 32 vs 4 [11.8%] of 34) at 6 months and the
improvement appeared to be sustained (10 [41.7%] of 24 vs 6 [20.0%] of 30) at 12
months. There was no change in the acne and hirsutism scores as well as serum T
levels in both arms.
CONCLUSION(S): We found a possible benefit in menstrual cyclicity but a lack of
improvement in hyperandrogenism in our Chinese population.
CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-09000670 (Chinese Clinical Trial
Registry).
|